Back to Directory
DJS Antibodies
Founded 2014
Antibody discovery biotech targeting GPCRs in inflammatory disease
DJS Antibodies is a biotechnology company developing monoclonal antibody therapeutics against G protein-coupled receptors and other previously intractable disease targets.
Its proprietary antibody discovery platform enables the generation of first-in-class antibodies against transmembrane proteins that have historically resisted biologics approaches.
The lead programme targets a receptor implicated in idiopathic pulmonary fibrosis and other fibrotic diseases.
DJS Antibodies was acquired by AbbVie in 2022 and continues to operate from its Oxford research facility.
Company Notes
Parent Company